HRP20090143T3 - N-oksidi kao predlijekovi derivata piperazina i piperidina - Google Patents

N-oksidi kao predlijekovi derivata piperazina i piperidina

Info

Publication number
HRP20090143T3
HRP20090143T3 HR20090143T HRP20090143T HRP20090143T3 HR P20090143 T3 HRP20090143 T3 HR P20090143T3 HR 20090143 T HR20090143 T HR 20090143T HR P20090143 T HRP20090143 T HR P20090143T HR P20090143 T3 HRP20090143 T3 HR P20090143T3
Authority
HR
Croatia
Prior art keywords
piperazine
piperidine derivatives
preparations
oxides
methyl
Prior art date
Application number
HR20090143T
Other languages
English (en)
Croatian (hr)
Inventor
S. M. Koopman Theodorus
J. Koster Hendrik
H. Van Amsterdam Peter
W. Feenstra Roelof
Verhage Marinus
C. Mccreary Andrew
B. Hesselink Mayke
Original Assignee
Solvay Pharmaceuticals B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals B.V. filed Critical Solvay Pharmaceuticals B.V.
Publication of HRP20090143T3 publication Critical patent/HRP20090143T3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HR20090143T 2005-08-22 2006-08-21 N-oksidi kao predlijekovi derivata piperazina i piperidina HRP20090143T3 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70982105P 2005-08-22 2005-08-22
EP05107671 2005-08-22
PCT/EP2006/065477 WO2007023141A1 (en) 2005-08-22 2006-08-21 N-oxides as prodrugs of piperazine & piperidine derivatives

Publications (1)

Publication Number Publication Date
HRP20090143T3 true HRP20090143T3 (hr) 2009-04-30

Family

ID=39246895

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090143T HRP20090143T3 (hr) 2005-08-22 2006-08-21 N-oksidi kao predlijekovi derivata piperazina i piperidina

Country Status (17)

Country Link
EP (1) EP1919883B1 (de)
JP (1) JP2009504799A (de)
KR (1) KR20080046205A (de)
AT (1) ATE417834T1 (de)
AU (1) AU2006283882B2 (de)
CA (1) CA2621158A1 (de)
DE (1) DE602006004363D1 (de)
DK (1) DK1919883T3 (de)
ES (1) ES2318783T3 (de)
HR (1) HRP20090143T3 (de)
IL (1) IL188903A0 (de)
NO (1) NO20081435L (de)
PL (1) PL1919883T3 (de)
PT (1) PT1919883E (de)
RU (1) RU2394821C2 (de)
SI (1) SI1919883T1 (de)
WO (1) WO2007023141A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
CA2654719A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising slv308 and a l-dopa
AU2007291234A1 (en) 2006-08-31 2008-03-06 Solvay Pharmaceuticals B.V. Titration schedule for bifeprunox for treating schizophrenia and kits for use therein
CN101711236B (zh) * 2007-04-12 2012-10-31 Nsab神经研究瑞典公司分公司 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物
EP2234990A1 (de) * 2008-01-15 2010-10-06 Abbott Healthcare Products B.V. Bifeprunox-derivate
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE503170A (de) * 1975-09-02
AU708053B2 (en) * 1996-03-29 1999-07-29 Duphar International Research B.V. Piperazine and piperidine compounds
UA71590C2 (en) * 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
US6911448B2 (en) * 2000-05-12 2005-06-28 Solvay Pharmaceuticals B.V. Piperazine and piperidine compounds
RU2301806C2 (ru) * 2002-01-16 2007-06-27 Янссен Фармацевтика Н.В. Прукалоприд-n-оксид

Also Published As

Publication number Publication date
PT1919883E (pt) 2009-03-26
EP1919883B1 (de) 2008-12-17
WO2007023141A1 (en) 2007-03-01
DK1919883T3 (da) 2009-04-14
RU2394821C2 (ru) 2010-07-20
IL188903A0 (en) 2008-04-13
DE602006004363D1 (de) 2009-01-29
ES2318783T3 (es) 2009-05-01
AU2006283882A1 (en) 2007-03-01
ATE417834T1 (de) 2009-01-15
JP2009504799A (ja) 2009-02-05
EP1919883A1 (de) 2008-05-14
RU2008110945A (ru) 2009-09-27
PL1919883T3 (pl) 2009-06-30
AU2006283882B2 (en) 2011-06-23
CA2621158A1 (en) 2007-03-01
SI1919883T1 (sl) 2009-04-30
KR20080046205A (ko) 2008-05-26
NO20081435L (no) 2008-05-16

Similar Documents

Publication Publication Date Title
NO20060973L (no) Pyridylderivater og deres anvendelse som tempeutiske midler
MEP52408A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
ATE387199T1 (de) Neue substanzen und verbindungen als protease- inhibitoren
NO20025590D0 (no) Fenylglycin-derivater
ATE442847T1 (de) Benzimidazol-derivate als mek-hemmer
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
DE602005023015D1 (de) Indolderivate als viruzide
UA94065C2 (en) Dihydropseudoerythromycin derivatives
BR0207278A (pt) Derivados de ftalazinona-piperidina como inibidores de pde4
HRP20090074T3 (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
ATE422198T1 (de) Arylsulfonylnaphthalinderivate als 5ht2a- antagonisten
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
MA28279A1 (fr) Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
ATE478054T1 (de) Benzimidazolderivate
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
ATE355265T1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
ATE457302T1 (de) Aromatische etherderivate als thrombin-hemmer
HRP20080027T3 (hr) 4-hidroksi-4-metil-piperidin-1-karboksilna kiselina (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid
MXPA05009282A (es) Derivados de anilina sustituidos.
WO2004067703A3 (en) 5ht7 antagonists and inverse agonists
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ATE409179T1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
NO20090332L (no) 4-amino-3-arylamino-6-arylpyrazol[3,4-D]pyrimidinderivater, fremgangsmater for deres fremstilling og dere anvendelse som antivirale midler